BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 26293619)

  • 21. The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in myelomonocytic cells.
    De Lerma Barbaro A; Procopio FA; Mortara L; Tosi G; Accolla RS
    Eur J Immunol; 2005 Feb; 35(2):603-11. PubMed ID: 15627980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of major histocompatibility (MHC) class II human leukocyte antigen-DR alpha gene expression in thyrocytes by single strand binding protein-1, a transcription factor that also regulates thyrotropin receptor and MHC class I gene expression.
    Balducci-Silano PL; Suzuki K; Ohta M; Saito J; Ohmori M; Montani V; Napolitano G; Shong M; Taniguchi SI; Pietrarelli M; Lavaroni S; Mori A; Singer DS; Kohn LD
    Endocrinology; 1998 May; 139(5):2300-13. PubMed ID: 9564838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of MHC class II antigen expression in trophoblast cells results from a lack of class II transactivator (CIITA) gene expression.
    Murphy SP; Tomasi TB
    Mol Reprod Dev; 1998 Sep; 51(1):1-12. PubMed ID: 9712312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Major histocompatibility complex class II transactivator (CIITA) hammer- head ribozyme transfer inhibits major histocompatibility complex class II (MHC-II) expression in Jukart cells].
    Guo R; Zou P; Song YP; Ma J; Lu HZ; Cao YL; Tong YJ
    Zhonghua Er Ke Za Zhi; 2003 Dec; 41(12):925-8. PubMed ID: 14723817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical analysis of HLA class II antigens and tumor infiltrating mononuclear cells in renal cell carcinoma: correlation with clinical and histopathological data.
    Brasanac D; Marković-Lipkovski J; Hadzi-Djokić J; Müller GA; Müller CA
    Neoplasma; 1999; 46(3):173-8. PubMed ID: 10613593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma.
    Wei B; Yu M; Yao J; Jiang M; An J; Yang J; Lin J; Zhao Y; Zhu Y
    Front Immunol; 2021; 12():657951. PubMed ID: 34531849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma.
    Ghatalia P; Gordetsky J; Kuo F; Dulaimi E; Cai KQ; Devarajan K; Bae S; Naik G; Chan TA; Uzzo R; Hakimi AA; Sonpavde G; Plimack E
    J Immunother Cancer; 2019 May; 7(1):139. PubMed ID: 31138299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HLA-DR and CD74 Expression and the Immune Microenvironment in Renal Cell Carcinoma.
    Miura Y; Anami T; Yatsuda J; Motoshima T; Oka S; Suyama K; Inoshita N; Kinowaki K; Urakami S; Kamba T; Komohara Y
    Anticancer Res; 2021 Jun; 41(6):2841-2848. PubMed ID: 34083274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive Analyses Revealed Eight Immune Related Signatures Correlated With Aberrant Methylations as Prognosis and Diagnosis Biomarkers for Kidney Renal Papillary Cell Carcinoma.
    Luo Y; Chen D; Xing XL
    Clin Genitourin Cancer; 2023 Oct; 21(5):537-545. PubMed ID: 37455213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunological study on renal cell carcinoma in dialysis patients with acquired cystic disease of kidneys].
    Onishi T; Machida T; Masuda F; Torii S; Shirakawa H; Hatano T; Makino H
    Nihon Hinyokika Gakkai Zasshi; 1991 Nov; 82(11):1800-6. PubMed ID: 1762269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of HLA-G expression in renal cell carcinoma.
    Li BL; Lin A; Zhang XJ; Zhang X; Zhang JG; Wang Q; Zhou WJ; Chen HX; Wang TJ; Yan WH
    Tissue Antigens; 2009 Sep; 74(3):213-21. PubMed ID: 19531101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity.
    Sartoris S; Valle MT; Barbaro AL; Tosi G; Cestari T; D'Agostino A; Megiovanni AM; Manca F; Accolla RS
    J Immunol; 1998 Jul; 161(2):814-20. PubMed ID: 9670958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The dependence for leukocyte function-associated antigen-1/ICAM-1 interactions in T cell activation cannot be overcome by expression of high density TCR ligand.
    Abraham C; Griffith J; Miller J
    J Immunol; 1999 Apr; 162(8):4399-405. PubMed ID: 10201975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells.
    Satoh A; Toyota M; Ikeda H; Morimoto Y; Akino K; Mita H; Suzuki H; Sasaki Y; Kanaseki T; Takamura Y; Soejima H; Urano T; Yanagihara K; Endo T; Hinoda Y; Fujita M; Hosokawa M; Sato N; Tokino T; Imai K
    Oncogene; 2004 Nov; 23(55):8876-86. PubMed ID: 15467734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extracting tumor tissue immune status from expression profiles: correlating renal cancer prognosis with tumor-associated immunome.
    Teltsh O; Porgador A; Rubin E
    Oncotarget; 2015 Oct; 6(32):33191-205. PubMed ID: 26384298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.
    Mulders P; Tso CL; Gitlitz B; Kaboo R; Hinkel A; Frand S; Kiertscher S; Roth MD; deKernion J; Figlin R; Belldegrun A
    Clin Cancer Res; 1999 Feb; 5(2):445-54. PubMed ID: 10037196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TGF-beta1 down-regulates induced expression of both class II MHC and B7-1 on primary murine renal tubular epithelial cells.
    Banu N; Meyers CM
    Kidney Int; 1999 Sep; 56(3):985-94. PubMed ID: 10469366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
    Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
    Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
    J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells.
    Morimoto Y; Toyota M; Satoh A; Murai M; Mita H; Suzuki H; Takamura Y; Ikeda H; Ishida T; Sato N; Tokino T; Imai K
    Br J Cancer; 2004 Feb; 90(4):844-52. PubMed ID: 14970863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.